MIM specialist Phillips-Medisize Corporation announced plans to open a new 80,000 ft2 manufacturing facility on its Wisconsin, USA, campus. The facility manufactures high volume prefilled drug delivery systems, and is planned to be complete in 2017.
‘This expansion illustrates our continued commitment and investment in the design and manufacturing of drug delivery devices for biopharmaceutical companies, globally,’ said Matt Jennings, CEO and president of Phillips-Medisize, a Molex company. ‘Expanding in Menomonie adds to our manufacturing capacity to produce fully assembled and packaged drug delivery devices.’
This story is reprinted from material from Phillips-Medisize, with editorial changes made by Materials Today. The views expressed in this article do not necessarily represent those of Elsevier.